Drugs /

sorafenib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
sorafenib
Trade Name(s):
Nexavar
NCI Definition [1]:
A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for sorafenib

Sorafenib has been investigated in 42 clinical trials, of which 28 are open and 14 are closed. Of the trials investigating sorafenib, 7 are phase 1 (5 open), 6 are phase 1/phase 2 (3 open), 17 are phase 2 (10 open), 2 are phase 2/phase 3 (2 open), 8 are phase 3 (7 open), 1 is phase 4 (1 open), and 1 is no phase specified (0 open).

FLT3 ITD, PML-RARA Fusion, and t(15;17)(q22;q12) are the most frequent biomarker inclusion criteria for sorafenib clinical trials.

Hepatocellular carcinoma, acute myeloid leukemia, and myelodysplastic syndromes are the most common diseases being investigated in sorafenib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sorafenib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sorafenib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sorafenib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bay 43-9006, Nexavar, sorafenib, sorafenib n-oxide, sorafenib (substance), n-(4-chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(n-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, sorafenib, sorafenib, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-2-pyridinecarboxamide, sorafenib (product), 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, sorafenibum, sorafenib [chemical/ingredient]
Drug Categories [2]:
RET inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
BRAF, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET
NCIT ID [1]:
C61948
SNOMED ID [1]:
F-62122

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.